ISSWSH ISSUES IMPORTANT UPDATES FOR HSDD THERAPIES

ISSWSH is pleased to provide the following updates related to therapies for Hypoactive Sexual Desire Disorder or HSDD. The FDA has updated prescribing information for flibanserin, removed the REMS certification requirement for prescribers and pharmacists, and updated safety information related to the alcohol contraindication. In addition, bremelanotide has now been approved for treatment of HSDD. Please see the attached news release related to these two therapies for more specific information and references.

News Release

Save the Date

ISSWSH Genitopelvic Pain Course 2022-2023

Multiple Dates
Virtual
Visit the Course Website

ISSWSH Fall Course 2022

November 17-20, 2022   132 days left
DoubleTree Resort - Paradise Valley - Scottsdale, AZ
Visit the Course Website

ISSWSH Annual Meeting 2023

March 2-5, 2023   237 days left
Marriott St. Louis Grand - St. Louis, MO
Visit the Meeting Website

Latest Tweets

ISSWSH is excited to provide an innovative virtual course on genitopelvic pain. This course will include six webina… https://t.co/QssjknMbyM ISSWSH
ISSWSH remains committed to affirming & supporting the sexual rights of all people worldwide. We support the World… https://t.co/hUJeaT98Vc ISSWSH
Sign up for the ISSWSH Genitopelvic Pain Course to attend the first webinar in the six course series. This webinar… https://t.co/ucRRUFPhCs ISSWSH

Contact Details

ISSWSH Executive Office
14305 Southcross Dr
Suite 100
Burnsville, MN 55306
USA

Phone: +1 (952) 683 9025
Fax: +1 (952) 314 8212
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow Us

On Twitter
On Facebook
On Instagram